Karyopharm and menarini group receive full marketing authorization from the uk medicines & healthcare products regulatory agency for nexpovio® (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

– based on results from phase 3 boston study, marketing authorization expands multiple myeloma indication – newton, mass. and florence, italy , feb. 21, 2023 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the menarini group ("menarini"), a privately-held, leading international pharmaceutical company, today announced that the united kingdom's (uk) medicines and healthcare products regulatory agency (mhra) has granted full marketing authorization for nexpovio® (selinexor), a first-in-class, oral exportin 1 (xpo1) inhibitor, in combination with once-weekly bortezomib (velcade®) and low-dose dexamethasone (svd) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
KPTI Ratings Summary
KPTI Quant Ranking